Modelo predictivo in vitro de desensibilización rápida mastocito IgEaplicación clínica a quimioterápicos, anticuerpos monoclonales, antibióticos y alimentos en pacientes con anafilaxia

Abstract

Desensitization protocols allow the safe administration of first-line therapies including chemotherapy agents, monoclonal antibodies or antibiotics in patients who have presented with hypersensitivity reactions to the offending drug. Molecular mechanisms involved in desensitization are not fully understood and together with the lack of in vitro models for desensitization make it difficult to be expand the use of this protocols to food allergies, which have a prevalence of approximately 3% of adult European population and 8% of paediatric European population. Many patients who have presented with previous anaphylactic reaction against food present with new anaphylactic reactions to them when accidentally re-exposed. During this project we propose a first step where relevance and future applications that would be made open to use by means of obtaining an in vitro model able to predict the optimal parameters needed to desensitize a patient in and individualized way are described. The steps followed to obtain this model able to use human serums to sensitize human or humanized mast cells for later activation and desensitization with the allergen to which the patient is allergic to are also described. In a second step, clinical parameters for desensitization in patients who have suffered hypersensitivity reactions to chemotherapy drugs, monoclonal antibodies or antibiotics to predict the efficacy, safety and applicability of desensitization are studied. Several parameters like clinical severity during the initial reaction or desensitization, skin tests, response after several desensitizations and clinical results of desensitization will be analysed. This analysis will be based on 3 recent publications by the researcher group of this study where the author of this project is included as first author in two of them. This study was performed at Rheumatology, Immunology and Allergy Department of Brigham and Women’s Hospital, Harvard University affiliated, Boston, USA